Literature DB >> 12712872

[Interaction of donepezil and muscular blockers in Alzheimer's disease].

J Sánchez Morillo1, A Demartini Ferrari, A Roca de Togores López.   

Abstract

A 75-years-old man with Alzheimer's disease, treated with the cholinesterase inhibitor donepezil for 14 months, was scheduled for left colectomy under general anesthesia. During the procedure, succinylcholine-induced relaxation was prolonged and the effect of atracurium besylate was inadequate even at higher doses than those indicated for the patient's weight. Cholinesterase blood tests performed 10 months, 1 month and 10 days before surgery had demonstrated a gradual decrease in the duration of activity of the enzyme. Such an effect, which has been described for cholinesterase inhibitors like neostigmine and donepezil, would explain the prolonged effect of succinylcholine. After ruling out other causes for resistance to atracurium, we conclude that donepezil or its metabolites acted on muscle plaque, blocking acetylcholine hydrolysis and antagonizing atracurium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12712872

Source DB:  PubMed          Journal:  Rev Esp Anestesiol Reanim        ISSN: 0034-9356


  5 in total

Review 1.  Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists.

Authors:  Danièle Bentué-Ferrer; Olivier Tribut; Elisabeth Polard; Hervé Allain
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  Alzheimer's disease, anesthesia and the cholinergic system.

Authors:  Mukul C Kapoor
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

3.  Donepezil: A cause of inadequate muscle relaxation and delayed neuromuscular recovery.

Authors:  Alka Bhardwaj; Sudhindra Dharmavaram; Sonia Wadhawan; Anjali Sethi; Poonam Bhadoria
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

4.  Donepezil-related inadequate neuromuscular blockade during laparoscopic surgery: A case report.

Authors:  Eun-A Jang; Tae-Young Kim; Eu-Gene Jung; Seongtae Jeong; Hong-Beom Bae; Seongheon Lee
Journal:  World J Clin Cases       Date:  2020-11-06       Impact factor: 1.337

5.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.